GiantPanda.That’s how the crook evil IBs con cheat retail investors, twist and spin Buy and Sell calls to benefit their big clients only

Boycott all MACQUARIE call warrants!!!

Ban all Call Warrants!!!

How could useless Bursa and SC let evil IBs issue call warrants on other companies to encourage gambling??

KARMA WILL HIT THOSE EVIL ONES VERY HARD
10/09/2020 6:10 PM

Stock markets...All Mr. Markets are like this n like that...this is a stock markets...

pBlue Yes, their research can probably be trusted just not their sale team. Their article is misleading in its structure.

If you look carefully at their article, they are taking about a scenario where the glove demand has returned to normal, aka the pandemic has ended. They put that date around FY22.

So once the pandemic is over, and glove demand returns to normal in FY22, Macquarie predicts TG will be able to maintain a TP of RM5.40 (base scenario). Bull scenario it could go as high as RM20.40, with a bear scenario of RM2.80.

Also stated with their article, Macquarie predicts an EPS of RM1.29 for FY2021. Given TG has a 50% dividend policy, it means 64.5 dividend for 2021.

So if we believe Mcquarie... TG is now at a price very near to what it will be able to maintain once the pandemic ends in 2022-2023. And we should expect a dividend of 12sen for this quarter. And 64.5 dividend in FY2021. So people who bought TG today will look forward to a 4% annual dividend for 2020, and 10% dividend for 2021.

And very little down side to their shares once the pandemic ends.

This is the base scenario.

If the glove bull continues.. well TG could rise upto RM20.80... And given the covid19 pandemic is uncontrolled and we are entering flu season... well glove demand will rise as more Covid19 patients flood the hospitals.

Yeah i know... TA people will call me foolish for believing in FA. But there you go.

If everyone throw their TG shares tomorrow, I will be around to buy as much as I can... i mean... 10% dividend per year? Who can say no to that?

Posted by lclwyp > Sep 10, 2020 4:16 PM | Report Abuse
On 26/8/20, Macquarie gave TP 30.40. Now (2 weeks later), almost cut half to 16.20 (5.40 x3)
Their research can be trusted?
10/09/2020 5:14 PM

Thanks.@pBlue.
TA wise very Simple...#10.30am...alrrady below RSI30...Oversold...almost all genuine glove counters...So the possibility of a Technical Rebound is high...So maybe tomorrow is Friday...looking bearish...but we never know... Malaysia Boleh...⊙﹏⊙

Bought...@3.28.

Added...@2.08.

Friendship Foreign funds are coming in to buy cheap and retailers are buying back

Local funds managers will panic buy back in second session
10/09/2020 1:57 PM

Bought back...@6.18.

TOP GLOVE buyback 1.392million shares at RM7.11 - RM7.21
Author: gloveharicut Publish date: Wed, 9 Sep 2020, 7:26 PM

{{{PM me to join GLOVE Private Discussion Room}}}

I invite you to read my blog and make a smart GLOVE decision.

https://klse.i3investor.com/blogs/gloveharicut/blidx.jsp

TOP GLOVE buyback 1.392million shares at RM7.11 - RM7.21

https://klse.i3investor.com/insider/company/shareBuyback/7113/09-Sep-2020/69436_1164386400.jsp

#Efficient Management.

2020 SEP 8.
GENEVA - World Health Organization chief Tedros Adhanom Ghebreyesus said on Monday the world must be better prepared for the next pandemic, as he called on countries to invest in public health.

More than 27.19 million people have been reported to be infected by the novel coronavirus globally and 888,326​ have died, according to a Reuters tally, since the first cases were identified in China in December 2019.

"This will not be the last pandemic," Tedros told a news briefing in Geneva. "History teaches us that outbreaks and pandemics are a fact of life. But when the next pandemic comes, the world must be ready – more ready than it was this time."

REUTERS.

2020 SEP 8.
GENEVA - World Health Organization chief Tedros Adhanom Ghebreyesus said on Monday the world must be better prepared for the next pandemic, as he called on countries to invest in public health.

More than 27.19 million people have been reported to be infected by the novel coronavirus globally and 888,326​ have died, according to a Reuters tally, since the first cases were identified in China in December 2019.

"This will not be the last pandemic," Tedros told a news briefing in Geneva. "History teaches us that outbreaks and pandemics are a fact of life. But when the next pandemic comes, the world must be ready – more ready than it was this time."

REUTERS.

Chinese made Vaccines.

https://www.globaltimes.cn/content/1200192.shtml

Be Realistic...(｡◕‿◕｡)➜

https://www.theguardian.com/commentisfree/2020/sep/06/lets-get-real-no-vaccine-will-work-as-if-by-magic-returning-us-to-normal

China Vaccine News.

Indonesia has secured a commitment to be sent 20-30 million doses of the potential vaccine by the end of this year, some 80-130 million doses in first quarter of next year and 210 million doses for the remainder of 2021, she said.

“Therefore, if we talk about numbers, we have secured 290 million to 340 million for 2021,” she told reporters in a virtual briefing on Monday.

The first of the deals were secured when the two ministers visited China’s resort city Sanya on Hainan Island on Thursday, while the rest were negotiated with UAE officials in Abu Dhabi on Saturday.

In Sanya, Retno and Erick oversaw two deals between state-owned pharmaceuticals firm Bio Farma and China’s Sinovac Biotech that would give Indonesia the equivalent of 50 million doses of the potential vaccine from November to March and priority access for the rest of 2021.

Read also: Government, Bio Farma secure vaccine bulk supply from China's Sinovac

It will be supplied in the form of vaccine bulk, an aqueous form of the purified antigens, or vaccine, provided in a large container from which individual vials are filled.

Indonesia is already cooperating with Sinovac in the phase three clinical trial of the vaccine candidate, with tests being carried out on 1,620 volunteers in Bandung, West Java, since earlier this month.

The government has also looked into partnerships with two other Chinese drug manufacturers, SINOPHARM and CanSino Biologics.

BBIBP-CorV (Sinopharm/CNBG, China)

Now we’re into “old school” inactivated vaccines that are in phase 3 trials. Clinical trial data hasn’t been published here yet. I’ve seen BBIBP-CorV discussed as 1 or 2 vaccines, so I could be wrong here: I’m assuming it’s 2.

Sinopharm is state-run, with a corporate subsidiary, the China National Biotec Group (CNBG). BBIBP-CorV vaccine(s) has/have been through a phase 1/2 trial, with 1,120 people.

CNBG posted some interim results on their website in June, which reports positive antibody responses, but no detail on adverse effects. It has reportedly been said that adverse effects will be lower than other vaccines – which would not be surprising for inactivated vaccine.

The phase 3 trial is underway in Abu Dhabi, United Arab Emirates (UAE). UAE was reporting about 500 people or so with new confirmed Covid-19 a day in June, according to Wikipedia. It’s a country of about 10 million people. So there’s some virus circulating.

If I’m understanding the trial registry entry properly, this will surely be the first phase 3 trial with interim results. The trial measures effectiveness in protecting against infection just 14 days after the 2-injection vaccination course is completed.

Its for 15,000 adults with no upper age limit, with 2 groups of 5,000 people for each vaccine and a 5,000-person placebo group.
(It’s not specified what each of the 2 groups are, but it’s why I’m assuming there are 2 vaccines.)

China can reportedly produce 200 million or more doses of this vaccine a year, including using a new production facility that was scheduled for completion at the end of July.

A production deal has also been reported between UAE/China and Indonesia.

Those countries are Muslim majority and it's Halal. Malaysia probably will follow as per normal.

yanz77 Titijaya should at least issue a press statement regarding their involvement with Sinopharm and their future plans if a vaccine from Sinopharm is successfully produced. At least this could convince their investors.
06/09/2020 2:15 PM

If announce tonight... tomorrow limit up..n three days limit up...u have chance to buy at what Price...◉‿◉

Sinopharm vaccine from China arrives in Peru for clinical trial
Updated 2020.09.05 13:39 GMT+8

A coronavirus vaccine candidate from the Chinese pharmaceutical company Sinopharm arrived in Lima this Wednesday for the all-important Phase Three clinical trial.

Sinopharm's vaccine testing samples arrive in Peru.
Indonesia begins last phase of vaccine clinical trials.

As early in July, emergency used of Sinopharma vaccine for Sinopharmas' laboratory workers n other vaccines are involved like CanSino n Sinovac.

Sinopharma vaccine will finish its phase 3 trials by year end. And approved by China health authority.

China vaccine News.

Dr Altice highlighted three important requirements for Covid-19 vaccines — safety, efficacy and the manufacturing process.

The produced vaccine should be safe and work well without causing side effects. He also explained the three important phases in Covid-19 vaccine development process.

“The phases are Phase One, which is safety. This like the Moderna vaccine — about 10 patients or so, where we find the lowest dose required to produce the maximum antibody, that is immune response in healthy volunteers.

Phase Two involves patients in the hundreds and we ask the question how well is that vaccine working and those who need it.

“And then Phase Three is the classic randomised control trial that will take thousands of patients and it really asks the question for those who get exposed, is there a reduction in the likelihood of getting infected and how much of a reduction is there,”
said Dr Altice at the talk titled “#VirtualTalk UM and Yale: The Race to Covid’s End”.

He also mentioned that a wide range of tests should be done involving the elderly and children to study the effectiveness of a vaccine to develop immunity against the virus that causes Covid-19, as well as to avoid unintended consequences.

“There are some really important issues because this disease impacts more negatively those individuals who are older and who have immune compromised,” he said.

Furthermore, Dr Altice raised storage problems that will probably emerge in Covid-19 vaccination.

Usually, most vaccines for common conditions can be stored in refrigerators at home here. Those vaccines are easier to be delivered all over the world, including equatorial regions where Malaysia is located. But Covid-19 belongs to the family of single-stranded ribonucleic acid (RNA) viruses.

Unlike conventional vaccines, RNA vaccines should be stored at very low temperatures, said Dr Altice.

“The problem is that our experience with most RNA vaccines, which this will be most likely, have to be stored at incredibly low levels minus 80 degrees, which are typically research freezers, and it will be inaccessible for much of the world,” he said.

“So that’s a major sort of issue and then of course I would say we have to really think about prioritising who gets it.

“The places that will be most devastated will be the low and middle-income countries where there’s a lack of hospital beds and a lack of medical infrastructure to take care of people who get sick.”

He stressed that the producer of vaccines and cost are crucial factors to ensure the vaccine reaches those who really need it.

BBC reported.

Dr Altice highlighted three important requirements for Covid-19 vaccines — safety, efficacy and the manufacturing process.

The produced vaccine should be safe and work well without causing side effects. He also explained the three important phases in Covid-19 vaccine development process.

“The phases are Phase One, which is safety. This like the Moderna vaccine — about 10 patients or so, where we find the lowest dose required to produce the maximum antibody, that is immune response in healthy volunteers.

Phase Two involves patients in the hundreds and we ask the question how well is that vaccine working and those who need it.

“And then Phase Three is the classic randomised control trial that will take thousands of patients and it really asks the question for those who get exposed, is there a reduction in the likelihood of getting infected and how much of a reduction is there,”
said Dr Altice at the talk titled “#VirtualTalk UM and Yale: The Race to Covid’s End”.

He also mentioned that a wide range of tests should be done involving the elderly and children to study the effectiveness of a vaccine to develop immunity against the virus that causes Covid-19, as well as to avoid unintended consequences.

“There are some really important issues because this disease impacts more negatively those individuals who are older and who have immune compromised,” he said.

Furthermore, Dr Altice raised storage problems that will probably emerge in Covid-19 vaccination.

Usually, most vaccines for common conditions can be stored in refrigerators at home here. Those vaccines are easier to be delivered all over the world, including equatorial regions where Malaysia is located. But Covid-19 belongs to the family of single-stranded ribonucleic acid (RNA) viruses.

Unlike conventional vaccines, RNA vaccines should be stored at very low temperatures, said Dr Altice.

“The problem is that our experience with most RNA vaccines, which this will be most likely, have to be stored at incredibly low levels minus 80 degrees, which are typically research freezers, and it will be inaccessible for much of the world,” he said.

“So that’s a major sort of issue and then of course I would say we have to really think about prioritising who gets it.

“The places that will be most devastated will be the low and middle-income countries where there’s a lack of hospital beds and a lack of medical infrastructure to take care of people who get sick.”

He stressed that the producer of vaccines and cost are crucial factors to ensure the vaccine reaches those who really need it.

BBC reported.

World COVID-19.
Surgical glove makers struggle to keep pace with booming demand
(Top Gloves/Anas Zakwan/Handout via Reuters)
04 Sep 2020 11:42PM
(Updated: 05 Sep 2020 11:43PM)

Worldwide: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves - as for other types of personal protective equipment - is booming, leaving manufacturers struggling to keep up.

The global PPE market - from masks, gowns and gloves, to shoes and sanitising gels - is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

And, like other such products that were previously predominantly the domain of specialist medical personnel, the surgical glove has become much sought after even by the general public.

US-based Allied Market Research estimates that the global disposable gloves market amounted to US$6.8 billion in 2019, and is expected to nearly triple to US$18.8 billion by 2027.

Worldwide demand for personal protective equipment is booming as a result of the coronavirus
Worldwide demand for personal protective equipment is booming as a result of the coronavirus pandemic.

Just as worldwide shortages of masks and disinfectant gels have pushed up the prices of those products, single-use medical gloves have become increasingly difficult and costly to come by during the health crisis.

"We have health centres calling us every day trying to get their hands on gloves," said Sebastien Lenoble, director of Netherlands-based Shield Scientific, which markets gloves for medical, industrial and laboratory applications.

"These aren't our usual clients. They're coming to us because they're desperate to find gloves."

While the World Health Organization says that wearing rubber or latex gloves in public offers little protection against infection, they are becoming an increasingly common sight in shops and public transport around the world.

"We are observing a more than threefold increase in demand for examination gloves, and demand for surgical gloves has also increased significantly," said Monika Riedel, spokeswoman for Austrian company Semperit, whose Sempermed subsidiary makes between seven and eight billion gloves every year.

Malaysia is the world's biggest maker of rubber gloves, accounting for around 60 per cent of global exports.

CNN News.

Malaysia's glove makers struggle to meet booming demand
By AFP
September 5, 2020 @ 10:00am
- NSTP / FAIZ ANUAR

PARIS: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves – as for other types of personal protective equipment – is booming, leaving manufacturers struggling to keep up.

The global PPE market – from masks, gowns and gloves, to shoes and sanitising gels – is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

And, like other such products that were previously predominantly the domain of specialist medical personnel, the surgical glove has become much sought after even by the general public.

US-based Allied Market Research estimates that the global disposable gloves market amounted to US$6.8 billion in 2019, and is expected to nearly triple to US$18.8 billion by 2027.

Covid-19: Malaysia's Top Glove overwhelmed by international orders
Spike in demand for rubber gloves: Top Glove to the rescue
Top Glove now Malaysia's second-biggest company
Just as worldwide shortages of masks and disinfectant gels have pushed up the prices of those products, single-use medical gloves have become increasingly difficult and costly to come by during the health crisis.

Malaysia is the world's biggest maker of rubber gloves, accounting for around 60 per cent of global exports.

And according to the Malaysian manufacturers' association MARGMA, worldwide demand is projected to rise from 296 billion in 2019 to 330 billion this year.

Given the surge, the industry is forecasting a shortage that is expected to last well into next year, MARGMA said.

Malaysian manufacturer Top Glove, which describes itself as the world's biggest producer of rubber gloves, said it is seeing orders for 11-12 billion a month, compared with 4.5 billion prior to the pandemic.

As a result, customers must now wait nearly 600 days for their orders to be filled, compared with a normal delivery time of 30-40 days, said chief executive, Lim Wee Chai.

In addition, with raw materials in short supply, production costs are also rising.

"The shortage of raw material for our nitrile gloves and the disruption to the supply or production of other material such as packaging materials due to the global lockdown, has caused an increase in the production cost," said Top Glove.

That would be passed on to customers in the form of higher prices.

While health experts argue that regular handwashing offers better protection against Covid-19 than gloves, the current boom for PPE is expected to pose another problem further down the line.

Environmental campaigners are concerned that millions of tonnes of single-use gloves will end up polluting the oceans.

- AFP.
05/09/2020 1:31 PM

Malaysia's glove makers struggle to meet booming demand
By AFP
September 5, 2020 @ 10:00am
- NSTP / FAIZ ANUAR

PARIS: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves – as for other types of personal protective equipment – is booming, leaving manufacturers struggling to keep up.

The global PPE market – from masks, gowns and gloves, to shoes and sanitising gels – is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

And, like other such products that were previously predominantly the domain of specialist medical personnel, the surgical glove has become much sought after even by the general public.

US-based Allied Market Research estimates that the global disposable gloves market amounted to US$6.8 billion in 2019, and is expected to nearly triple to US$18.8 billion by 2027.

Covid-19: Malaysia's Top Glove overwhelmed by international orders
Spike in demand for rubber gloves: Top Glove to the rescue
Top Glove now Malaysia's second-biggest company
Just as worldwide shortages of masks and disinfectant gels have pushed up the prices of those products, single-use medical gloves have become increasingly difficult and costly to come by during the health crisis.

Malaysia is the world's biggest maker of rubber gloves, accounting for around 60 per cent of global exports.

And according to the Malaysian manufacturers' association MARGMA, worldwide demand is projected to rise from 296 billion in 2019 to 330 billion this year.

Given the surge, the industry is forecasting a shortage that is expected to last well into next year, MARGMA said.

Malaysian manufacturer Top Glove, which describes itself as the world's biggest producer of rubber gloves, said it is seeing orders for 11-12 billion a month, compared with 4.5 billion prior to the pandemic.

As a result, customers must now wait nearly 600 days for their orders to be filled, compared with a normal delivery time of 30-40 days, said chief executive, Lim Wee Chai.

In addition, with raw materials in short supply, production costs are also rising.

"The shortage of raw material for our nitrile gloves and the disruption to the supply or production of other material such as packaging materials due to the global lockdown, has caused an increase in the production cost," said Top Glove.

That would be passed on to customers in the form of higher prices.

While health experts argue that regular handwashing offers better protection against Covid-19 than gloves, the current boom for PPE is expected to pose another problem further down the line.

Environmental campaigners are concerned that millions of tonnes of single-use gloves will end up polluting the oceans.

- AFP
05/09/2020 12:43 PM
05/09/2020 1:31 PM

Malaysia's glove makers struggle to meet booming demand
By AFP
September 5, 2020 @ 10:00am
- NSTP / FAIZ ANUAR

PARIS: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves – as for other types of personal protective equipment – is booming, leaving manufacturers struggling to keep up.

The global PPE market – from masks, gowns and gloves, to shoes and sanitising gels – is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

And, like other such products that were previously predominantly the domain of specialist medical personnel, the surgical glove has become much sought after even by the general public.

US-based Allied Market Research estimates that the global disposable gloves market amounted to US$6.8 billion in 2019, and is expected to nearly triple to US$18.8 billion by 2027.

Covid-19: Malaysia's Top Glove overwhelmed by international orders
Spike in demand for rubber gloves: Top Glove to the rescue
Top Glove now Malaysia's second-biggest company
Just as worldwide shortages of masks and disinfectant gels have pushed up the prices of those products, single-use medical gloves have become increasingly difficult and costly to come by during the health crisis.

Malaysia is the world's biggest maker of rubber gloves, accounting for around 60 per cent of global exports.

And according to the Malaysian manufacturers' association MARGMA, worldwide demand is projected to rise from 296 billion in 2019 to 330 billion this year.

Given the surge, the industry is forecasting a shortage that is expected to last well into next year, MARGMA said.

Malaysian manufacturer Top Glove, which describes itself as the world's biggest producer of rubber gloves, said it is seeing orders for 11-12 billion a month, compared with 4.5 billion prior to the pandemic.

As a result, customers must now wait nearly 600 days for their orders to be filled, compared with a normal delivery time of 30-40 days, said chief executive, Lim Wee Chai.

In addition, with raw materials in short supply, production costs are also rising.

"The shortage of raw material for our nitrile gloves and the disruption to the supply or production of other material such as packaging materials due to the global lockdown, has caused an increase in the production cost," said Top Glove.

That would be passed on to customers in the form of higher prices.

While health experts argue that regular handwashing offers better protection against Covid-19 than gloves, the current boom for PPE is expected to pose another problem further down the line.

Environmental campaigners are concerned that millions of tonnes of single-use gloves will end up polluting the oceans.

- AFP
05/09/2020 12:43 PM

Malaysia's glove makers struggle to meet booming demand
By AFP
September 5, 2020 @ 10:00am
- NSTP / FAIZ ANUAR

PARIS: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves – as for other types of personal protective equipment – is booming, leaving manufacturers struggling to keep up.

The global PPE market – from masks, gowns and gloves, to shoes and sanitising gels – is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

And, like other such products that were previously predominantly the domain of specialist medical personnel, the surgical glove has become much sought after even by the general public.

US-based Allied Market Research estimates that the global disposable gloves market amounted to US$6.8 billion in 2019, and is expected to nearly triple to US$18.8 billion by 2027.

Covid-19: Malaysia's Top Glove overwhelmed by international orders
Spike in demand for rubber gloves: Top Glove to the rescue
Top Glove now Malaysia's second-biggest company
Just as worldwide shortages of masks and disinfectant gels have pushed up the prices of those products, single-use medical gloves have become increasingly difficult and costly to come by during the health crisis.

Malaysia is the world's biggest maker of rubber gloves, accounting for around 60 per cent of global exports.

And according to the Malaysian manufacturers' association MARGMA, worldwide demand is projected to rise from 296 billion in 2019 to 330 billion this year.

Given the surge, the industry is forecasting a shortage that is expected to last well into next year, MARGMA said.

Malaysian manufacturer Top Glove, which describes itself as the world's biggest producer of rubber gloves, said it is seeing orders for 11-12 billion a month, compared with 4.5 billion prior to the pandemic.

As a result, customers must now wait nearly 600 days for their orders to be filled, compared with a normal delivery time of 30-40 days, said chief executive, Lim Wee Chai.

In addition, with raw materials in short supply, production costs are also rising.

"The shortage of raw material for our nitrile gloves and the disruption to the supply or production of other material such as packaging materials due to the global lockdown, has caused an increase in the production cost," said Top Glove.

That would be passed on to customers in the form of higher prices.

While health experts argue that regular handwashing offers better protection against Covid-19 than gloves, the current boom for PPE is expected to pose another problem further down the line.

Environmental campaigners are concerned that millions of tonnes of single-use gloves will end up polluting the oceans.

- AFP
05/09/2020 12:43 PM

Malaysia's glove makers struggle to meet booming demand
By AFP
September 5, 2020 @ 10:00am
- NSTP / FAIZ ANUAR

PARIS: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves – as for other types of personal protective equipment – is booming, leaving manufacturers struggling to keep up.

The global PPE market – from masks, gowns and gloves, to shoes and sanitising gels – is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

And, like other such products that were previously predominantly the domain of specialist medical personnel, the surgical glove has become much sought after even by the general public.

US-based Allied Market Research estimates that the global disposable gloves market amounted to US$6.8 billion in 2019, and is expected to nearly triple to US$18.8 billion by 2027.

Covid-19: Malaysia's Top Glove overwhelmed by international orders
Spike in demand for rubber gloves: Top Glove to the rescue
Top Glove now Malaysia's second-biggest company
Just as worldwide shortages of masks and disinfectant gels have pushed up the prices of those products, single-use medical gloves have become increasingly difficult and costly to come by during the health crisis.

Malaysia is the world's biggest maker of rubber gloves, accounting for around 60 per cent of global exports.

And according to the Malaysian manufacturers' association MARGMA, worldwide demand is projected to rise from 296 billion in 2019 to 330 billion this year.

Given the surge, the industry is forecasting a shortage that is expected to last well into next year, MARGMA said.

Malaysian manufacturer Top Glove, which describes itself as the world's biggest producer of rubber gloves, said it is seeing orders for 11-12 billion a month, compared with 4.5 billion prior to the pandemic.

As a result, customers must now wait nearly 600 days for their orders to be filled, compared with a normal delivery time of 30-40 days, said chief executive, Lim Wee Chai.

In addition, with raw materials in short supply, production costs are also rising.

"The shortage of raw material for our nitrile gloves and the disruption to the supply or production of other material such as packaging materials due to the global lockdown, has caused an increase in the production cost," said Top Glove.

That would be passed on to customers in the form of higher prices.

While health experts argue that regular handwashing offers better protection against Covid-19 than gloves, the current boom for PPE is expected to pose another problem further down the line.

Environmental campaigners are concerned that millions of tonnes of single-use gloves will end up polluting the oceans.

- AFP

diuleiloumei If coming TG QR good bombastic result, would there be another Bonus issued again ?
04/09/2020 11:17 AM

#2022...Maybe...1:1...◉‿◉

geary winwinvest I love red red babes
03/09/2020 4:52 PM

Red Red... Added...:-)
03/09/2020 4:56 PM

｡◕‿◕｡

winwinvest I love red red babes
03/09/2020 4:52 PM

Red Red... Added...:-)

HIV risk
CanSino n Russian Sputnik Vaccine.
Some scientists also worry an Ad5-based vaccine could increase chances of contracting HIV

Habis...all Vaccine bottling counters...limit down...(・o・)

Up...◉‿◉
https://www.klsescreener.com/v2/news/view/722003

calvintaneng Good afternoon

Someday Glove usage might become a norm like using tooth brush, toilet tissue or soap to wash hands

I visited Singpost office to post a letter

Every staff is using 2 medical gloves for protection in the post office.

So medical gloves are not just confined to hospitals anymore

It will become a way of life now

So careplus has a great future
31/08/2020 4:43 PM

Oh...New Normal... Everywhere...◉‿◉

Value growth investing strategy.
Buffett bought 5% of Japanese companies.

One likely reason these companies haven’t previously attracted interest from Omaha is that they’ve also traditionally been low-margin, cash-poor, debt-heavy, and more concerned with the interests of their corporate siblings than their shareholders.

As my colleague Anjani Trivedi has written, that has started to change over the past decade as leverage plummeted and the management plans guiding their activities moved from hazy strategic promises toward harder financial benchmarks, such as free cash flow and return on equity.

That's to say, conservative growth of owners earnings or free cash flow, after capex...debt to equity below...@1...Or long term debt below Cash n Equivalent. Above average Dupont ROE...@>12%.

Berkshire Hathaway said it has acquired slightly more than 5per cent of the shares in five large Japanese companies, marking a departure for Chairman Warren Buffett as he looks outside the United States to bolster his conglomerate.

In a statement on Sunday, Buffett's 90th birthday, Berkshire said it acquired its stakes in Itochu, Marubeni, Mitsubishi, Mitsui & Co and Sumitomo over approximately 12 months.

Berkshire said it intends to hold the investments for the long term, and may boost its stakes to 9.9 per cent. A Berkshire insurance business, National Indemnity, is holding the shares.

"I am delighted to have Berkshire Hathaway participate in the future of Japan," Buffett said in a statement. "The five major trading companies have many joint ventures throughout the world and are likely to have more.... I hope that in the future there may be opportunities of mutual benefit."

REUTERS.

Value_Investor_888 Some ppl like to create fear here when he had sold his holding. By the way, why want to talk bad on the stocks that you don't have or if you do not interest into? Why dont spend your time to pick up the stocks that you think can give you good returns instead of wasting your time here to talk bad (bad karma sure will hit you if you continue to do that)? I really can not understand why people have such bad behaviour and bad atttitude. I think this is just a very simple and basic rules: do not talk bad on any stocks that you dont have as this could be other's ppl rice bowl....you have your own rice bowl, other have thier own rice bowl as well...thus, why need to talk bad on the stocks that you dont have? WHY?? The cakes are on the table, if you have fate and good enough, just take some from the table, you can earn and all can earn as well. So, why need to talk bad here?
31/08/2020 3:30 PM

Let it be lah...Not only here...all pure gloves counters...he go n talk nonsense...Gloves counters most of them already have sustainable earnings...plus these few months... of exponential earnings growth...sales n margins both unbelievable growth...those who don't know how to take advantage...really I don't know what to say anymore. Probably their fate or luck are blocked by big walls or dark clouds...they cannot see...ಠ︵ಠ

Those vaccine counters, plus others core business that aren't really good...some are losing money n cash burnt for years...Even they can profit from vaccine sales n increase margins...they still can break even only. Maybe one or two still can pay extra dividend only...not much about bonus issues n special dividend.

Of course...many are talking...when gloves overcapacity can happen...wait for most front lines workers, army, naval n air force personnel n urban citizens are vaccinated...then...WHO announce... Covid19 is OVER...then only u sell some. But in between those price appreciation...we Must bring down our cost of capital or in other words...High Margin of Safety.

(◠‿◕)

Jeff5142 Karex's new glove factory in Thailand possibly will be its new customer.
29/08/2020 8:57 PM.

Yup... Actually...@60% of its sales are in Thailand...:-)

All healthcare counters.
https://www.klsescreener.com/v2/news/view/721969

stockraider Gloves rally macam playing old broken records mah...!!

When peak demand

excess capacity and many competitors coming

vaccine coming

Where got future growth leh ??

Don't worry lah... tomorrow all... Upswings... especially gloves counters n medical related products...plus some in vaccine bottling counters...but won't limit up so high lah...slow n steady now...:-)

Andrew Lo, an economist at the Massachusetts Institute of Technology, applauds this development.

He points out that companies have been fleeing the vaccine field in recent decades, because the profit margin on most vaccines is so thin.

"The fact that we now have more companies getting into the vaccine business because of Covid-19 is a tremendously positive aspect of this pandemic,” he says.

Chinese state firm sinopharm has been vaccinating key workers before trials for safety and effectiveness have been concluded.

But the changing economics of vaccine development have thrown up new ethical dilemmas. Nobody is suggesting that executives at Moderna and Inovio – US biotech firms working on experimental Covid-19 vaccines using technology that has never been approved – broke any rules when they sold off stock in their own companies.

This is normal practice, once companies go public, partly because it allows executives to recoup their initial investment.

But Lo says legal scholars are currently debating whether those rules remain fit for purpose. And while the scholars debate, the spectacle of execs cashing in on unproven technology that taxpayers helped fund – in the middle of a pandemic, to boot – does nothing for public trust in scientists. “It creates a cynicism that’s understandable,” says Offit.

For Dawson, the bad behaviour now on display is evidence that commercial incentives are too dominant in the search for a vaccine.

He points out that other kinds of incentives were possible. The WHO could have offered a prize for the vaccine most likely to reduce the global burden of Covid-19, for example.
That might have given it some ownership of the final product, and power to ensure its equitable distribution.

Unfortunately, the chronically underfunded WHO doesn’t have the authority many people think it has. “People assume it’s this global power,” Dawson says, “but my university has a bigger budget than the WHO.”

Vaccine Controversy News.

JAKARTA: A more infectious mutation of the new coronavirus has been found in Indonesia, the Jakarta-based Eijkman Institute for Molecular Biology said on Sunday, as the Southeast Asian country's caseload surges.

Indonesia reported 2,858 new infections on Sunday, data by the health ministry showed, below the previous day's record 3,308 but above the past month's daily average. Its total number of cases was 172,053, with 7,343 COVID-19 fatalities.

The "infectious but milder" D614G mutation of the virus has been found in genome sequencing data from samples collected by the institute, deputy director Herawati Sudoyo told Reuters, adding that more study is required to determine whether that was behind the recent rise in cases.

The strain, which the World Health Organization said was identified in February and has been circulating in Europe and the Americas, has also been found in neighbouring Singapore and Malaysia.

Syahrizal Syarif, an epidemiologist with the University of Indonesia, warned Indonesians must remain vigilant, as his modelling suggests the country may see its caseload rise to 500,000 by the end of the year.

"The situation is serious.... Local transmission currently is out of control," Syarif said, adding that the number of infections found daily could have been much higher if laboratories were able to process more specimens in a day.

The capital Jakarta on Sunday saw a record daily increase of more than 1,000 cases, which the city government linked to a higher mobility rate during a mid-August independence celebration.

"There needs to be an awareness and a collective effort, be it from the government or the people, in addressing the rising number of cases," Dwi Oktavia, an official at the Jakarta health agency, said in a statement, urging people to stay at home and wear a face mask when they must go out.

Covid 19 cannot be eradicated completely - Koon Yew Yin
Author: Koon Yew Yin Publish date: Mon, 31 Aug 2020, 10:25 AM

I have excerpted Dr Sheldon Campbell’s useful article for investors. Based on this article, the demand for medical gloves will continue to exceed supply. The selling prices for gloves will continue to go up higher and higher which should be reflected on glove stocks prices.

As COVID-19 cases continue to pile up across the country, many of us are wondering when—and if—the highly infectious and potentially deadly virus is ever going to go away. According to a top Yale pathologist, the answer is no. It is going to be with us "indefinitely."

"It's going to tail off, not end abruptly," Sheldon Campbell, MD, Ph.D., a laboratory medicine specialist at Yale Medicine and professor of laboratory medicine at Yale School of Medicine, tells Eat This, Not That! Health. "I think COVID-19 will be with us indefinitely." Read on to find out what they are, and to get through this pandemic at your healthiest, don't miss these Sure Signs You've Already Had Coronavirus.

'We're Unlikely to Eradicate It"

Dr. Campbell explains that despite the fact that the measles vaccine was developed in 1963 (enhanced in 1968 and MMR in '71), is "absolutely superb," fifty years later it is still not eradicated. "COVID is quite infectious, there are many asymptomatic cases to maintain it in a population, so we're unlikely to eradicate it like we did SARS," he adds.

And while top researchers like Francis Collins and Anthony Fauci are optimistic that a vaccine will be ready in 2021, he points out that there are still a lot of questions. "Will a vaccine block transmission or merely attenuate or limit symptoms? How many doses, how far apart? How effective will it be at preventing illness/death/transmission (each of those is a different number; the last one particularly hard to get at). And very critically, how many people will take it?" he asks.

As far as the testing realm, his area of interest, there are a lot of ideas sparking curiosity that could significantly improve the efficiency of testing—which could be incredibly beneficial as complementary approaches to controlling the virus. "Emerging technologies might produce a self-administered test that would detect high viral loads (the most infectious state) for around a dollar. They'd not detect every positive; but maybe most highly-infectious people," he reveals.

The Doctor's "Perhaps-Optimistic" Scenario

His best-case "perhaps-optimistic" scenario in achieving "new normal" status goes like this:

"The country figures out that, hey, masks aren't that awful—seems to be happening now to a degree. This current surge levels off and slowly declines because of social distancing, but bursts of infection continue in various places; possibly more so come winter. The vaccine trials go well. A trickle of cheap, rapid tests is also becoming available and are used in populations without vaccine coverage. We find and isolate patients sooner. Levels of disease decline to those seen in Europe now, say. New outbreaks are quickly contained, and the country gradually moves to a 'new normal' about a year from now."

How to Avoid COVID-19

Do what the scientists say: Wear your face mask, get tested if you think you have coronavirus, avoid crowds (and bars, and house parties), practice social distancing, only run essential errands, wash your hands regularly, disinfect frequently touched surfaces, and to get through this pandemic at your healthiest, don't miss these 37 Places You're Most Likely to Catch Coronavirus.

Latest: World Global coronavirus cases surpass 25 million.

NEW YORK: Global coronavirus cases surged past 25 million on Sunday (Aug 30), as India marked a worldwide record for daily new cases in the COVID-19 pandemic.

The data showed steady global growth as the disease's epicentre shifts again, with India taking centre stage from the United States and Latin America.

India's single-day tally of 78,761 new coronavirus infections on Sunday exceeded the one-day increase of 77,299 reported by the United States in mid-July, according to a Reuters tally.

The surge in India took the global caseload to 25,074,751.

The official number of global coronavirus cases is now at least five times the number of severe influenza illnesses recorded annually, according to World Health Organization data.

Around the world, there have been more than 840,000 deaths, considered a lagging indicator given the two-week incubation period of the virus. That has exceeded the upper range of 290,000 to 650,000 annual deaths linked to influenza.

India, the world's second-most populous country, is third behind the United States and Brazil in total caseload, but has consistently outpaced both in new daily cases since Aug 7.

Despite the surging case numbers, Prime Minister Narendra Modi has been pushing for a return to normalcy to lessen the economic pain of the pandemic, having imposed a strict early lockdown of the country's 1.3 billion people in March.

Latin America is the region with the most infections in the world, although some countries in the region are beginning to show a slight decline in infections.

In the United States, metrics on new cases, deaths, hospitalisations and test positivity rates are all declining, but there are emerging hotspots in the Midwest.

The global pace of new infections has steadied a little. It has taken about three weeks for the caseload to jump by 5 million cases to 25 million. That compared with the 19, 24 and 39 days it took, respectively, to add 5 million cases to the 20 million, 15 million and 10 million marks.

The rate of new daily cases has slowed to around 1.2 per cent over August so far. That compared with 1.7 per cent in July, 1.8 per cent in June, 2.1 per cent in May, 4.6 per cent in April and 7.7 per cent in March.

Health experts stress that official data almost certainly under-reports both infections and deaths, particularly in countries with limited testing capacity.

While COVID-19's trajectory still falls far short of the 1918 Spanish flu, which infected an estimated 500 million people, killing at least 10 per cent of patients, experts worry the available data is underplaying the true impact of the pandemic.

CNN News.

kens88 No worries on oversupply and glut.

I've worked in glove industry before.

To all: Not easy to set up glove production line. Line fabrication and fine tuning takes more than 18 months. This is for big 4 company. Others no experience company cannot even meet this time line. Not even China can do this.

Further, if big 4 is aggressive enough, they can buy out the entire nitrile supply. Other player got line, but no raw material.

Glove demand grows 10 to 12 % every yea

Thanks...:-)

stockraider Every countries & every gloves companies in the world are upping their capacity mah....!!

Alot of harm will be arriving soon mah...!!

Gloves is commodities mah....very easy upping capacity loh..!!

Analyse properly Don't anyhow barks in all glove forum...U can't even understand what's a commodity n a specialised product...aiyoo...ಠ︵ಠ

Demand and Supply of Glove.

Worldwide analysts estimate that the current global annual demand for gloves is as high as 400 billion to 600 billion, but the supply can only meet half of them at current production.

Malaysia n Thailand supply around...@75%...plus others only can supply up to...@>50%...of present demand of above 500 billion gloves.

Even with China ramping up its production lines n others for glove... probably in 1 or 2 years timeframe... glove demand increase by...@20% YOY.

Probably it takes to anticipate roughly around a year n half...to assume glove demand are tampering off...to normal n sustainable margins n profits.

(. ❛ ᴗ ❛.)

Ukraine, Indonesia report record rise in coronavirus cases: Live
Indonesia has reported biggest rise in infections for third successive day as Ukraine registers a record 2,481 cases.
by Zaheena Rasheed & Mersiha Gadzo
12 minutes ago

Indonesia has reported its biggest rise in infections for a third successive day, while Ukraine has also registered a record 2,481 cases.
Russia's coronavirus cases surpassed 980,000 after the country reported 4,829 new cases in the last 24 hours.

The number of coronavirus cases in Latin America surpassed seven million, as legislators in Argentina's capital passed a law allowing relatives to maintain a bedside vigil for patients dying of COVID-19.

South Korea extended social-distancing rules in the capital, Seoul, amid a triple-digit rise in cases, while India reported another record jump in daily cases.
New Delhi has reported the world's highest single-day caseload every day since August 7.

More than 24.7 million people around the world have been diagnosed with the coronavirus, and 16 million have recovered, according to Johns Hopkins University. More than 837,000 people have died.

Al Jazeera Live.

A case of coronavirus reinfection shows the complexities of the pandemic.

Antivirus: A weekly digest of the latest COVID-19 research
The scary thing finally happened: someone caught the coronavirus twice and got sicker the second time around.

A 25-year-old man in Nevada got COVID-19 in March, got better in April, and got sick again in May. He had worse symptoms on the second bout, bad enough that he had to be hospitalized.

Three other cases of confirmed reinfection were also reported this week: one in Hong Kong (the first documented case) and two in Europe.

These don’t necessarily make me any more worried about our vaccine prospects, though, and they don’t mean the pandemic will go on forever.

We have four documented cases of reinfection. But that’s out of the 24 million cases of this disease so far, and rare shit happens. Most experts expected that we’d see at least a few.

For months, there have been occasional, anecdotal reports of people testing positive for COVID-19 twice. None of those were proven to be reinfections.

For most of those people, the second test probably picked up residual, dead virus that was still floating around in people’s noses and throats after their first infection.

In these reinfection cases, though, researchers actually analyzed the virus from the first time the people got sick and compared it to the virus from the second time they got sick.

In each case, the two viruses had slightly different genetic sequences, showing that the second positive tests weren’t just leftover virus.

Here’s the other important thing: in the Hong Kong case, the second infection caused no symptoms at all. That means his immune system probably recognized the virus from the first infection and kept it in check.

We don’t know why that didn’t happen for the man in Nevada. He wasn’t tested for antibodies the first time he got sick, so it’s possible that he just didn’t make any. That’s the more encouraging option.

The other possibility is that he had antibodies, but they made the infection worse (it happens with other viruses, like dengue).

Nicole Wetsman. Aug 29, 2020. 10.00am.

USA.7:47 a.m. ET, August 29, 2020

Coronavirus outbreaks have been identified among several hundred students at Kansas State University.

The students at four sororities have been told to quarantine for 14 days from the day the outbreak was declared. Alpha Delta Pi and Alpha Xi Delta have six cases each, while Chi Omega and Kappa Delta have five cases apiece, the Riley County Health Department said Friday.

More than 60 US universities and colleges in at least 36 states have reported positive cases of Covid-19, and some have returned to remote learning to try to stem the spread. More than 8,700 infections among American college students and staff were reported through Friday, as the nation approaches 6 million confirmed cases.

At Kansas State, event permits associated with fraternity and sorority organizations through September 10 have been canceled or revoked.

At the university’s main campus, 364 students are in quarantine, and 167 students are in isolation, the school said in a news release, noting an increase of 149 in quarantine and 49 in isolation since last week. The entire student population reports a 3.82% positivity rate, the release states.

CNN's Hollie Silverman.

Powell says FED will seek inflation that average 2%.

He concedes, over the next 12 months, growth stocks are priced for perfection, and value may outperform.

“However, low nominal and real rates mean that discount factors for future cash flows will decline and with it, stock market valuations are likely to increase.

Stocks with a larger portion of cash flows further in the future (in other words growth stocks) experience a stronger rerating than high dividend stocks and stocks with less growth,” he said.

He highlighted companies with strong sales and earnings growth but low leverage, which have the space to further boost their growth through borrowing.

Bloomberg.

NZ Exchange...Cyberattack.

New Zealand Finance minister Grant Robertson said the Government Communications Security Bureau (GCSB) has been instructed to help New Zealand's Exchange (NZX), which has suffered periodic outages since Tuesday.

The National Security System has also been activated, requiring government agencies to work together, he told reporters at a press conference.

"There are limits to what I can say today about the action the government is taking behind the scenes due to significant security considerations," Robertson said. "We as a government are treating this very seriously."

The GCSB collects and analyzes intelligence, while providing cybersecurity for the country's critical infrastructure.

New Zealand is a member of the Five Eyes intelligence alliance, which also includes the United States, Britain, Australia and Canada.

The countries share a broad range of intelligence with one another and last year signed a cybersecurity pledge, along with 22 other nations, which provides for coordinated responses to cyberattacks.

GCSB New Zealand.

Jeff5142 Genm is loss making now 2.28. Esceramic is profit making now 1.11 only. Which will people chose to invest? Think carefully.
29/08/2020 8:26 AM

ESceram...the only listed company in Bursa... Malaysia heavyweight manufacturer in all types of Gloves Formers...N a manufacturing plant in Thailand...The others are smaller competitors...the closest one is Ceramtec...Not listed.

iCE COOL GenM may require some time to gain back their business to profit making, They require tourist expecially Singapore, China, Japan to spend in their resort/casino. At this moment, its quite impossible since the RMCO still ongoing and M'sia border is still close. Esceram, they business model is intact as glove maker require more product frm Esceram since the output are so huge, where glove maker require to change the former due to wear/tear. Do agree the valuation at this current price is abit high, but investor is looking at its future earning, and I believe their business will be very good in this coming Quarter, as long as the demand of glove is still high

"Never, ever invest on past n present earnings...U got to visualise yourself forward earnings growth for at least 4 to 6 quarters n anticipate its market's value...Price is what U pay...Value is what U get..," Druckenmiller n Buffett.

Covid19 Pandemic Will Linger...Face Mask Mandatory in many countries in EU...TopGlove surely will expand their production lines on mask from acquisition or collaboration...(・o・)

https://www.cnn.com/2020/08/29/europe/europe-covid-restrictions-intl/index.html

Japan Researchers Say Ozone Effective in Neutralising COVID-19.

TOKYO: Japanese researchers said on Wednesday (Aug 26) that low concentrations of ozone can neutralise coronavirus particles, potentially providing a way for hospitals to disinfect examination rooms and waiting areas.

Scientists at Fujita Health University told a news conference they had proven that ozone gas in concentrations of 0.05 to 0.1 parts per million (ppm), levels considered harmless to humans, could kill the virus.

The experiment used an ozone generator in a sealed chamber with a sample of coronavirus. The potency of the virus declined by more than 90 per cent when subjected to low level ozone for 10 hours.

“Transmission of the novel coronavirus may be reduced by continuous, low-concentration ozone treatment, even in environments where people are present, using this kind of system,” said lead researcher Takayuki Murata.

“We found it to be particularly effective in high-humidity conditions.”

Ozone, a type of oxygen molecule, is known to inactivate many pathogens, and previously experiments have shown that high concentrations, between 1-6 ppm, were effective against the coronavirus but potentially toxic to humans.

A recent study at the Georgia Institute of Technology showed that ozone may be effective in disinfecting gowns, goggles and other medical protective equipment.

Fujita Medical University Hospital, in Aichi prefecture central Japan, has installed ozone generators to reduce infection in waiting areas and patient rooms.

The university has also performed a clinical trial of Fujifilm’s Avigan drug on COVID-19 patients.

Fujita Health University.